(Q45859618)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16834734%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

A retrospective postlicensure survey of FEIBA efficacy and safety (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16834734%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16834734%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

0 references

D Dimichele

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16834734%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16834734%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16834734%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16834734%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16834734%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

352-362

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16834734%20AND%20SRC:MED&resulttype=core&format=json

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

Environmental and genetic factors influencing inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

The hemophilias--from royal genes to gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

Treatment of the bleeding inhibitor patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

Factor Xa and prothrombin: mechanism of action of FEIBA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

Monitoring the bioavailability of FEIBA with a thrombin generation assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

FEIBA safety profile in multiple modes of clinical and home-therapy application

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01284.X

10.1111/J.1365-2516.2006.01284.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16834734%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference